Thioredoxin reductase (RR), another antioxidant enzyme involved in reduction reactions in vivo, has also been implicated in the development of ovarian cancer, and studies have confirmed that inhibitors of RR, such as auranofin (AF), can be used to treat ovarian cancer by depleting GSH and promoting oxidative stress [129]. This evidence concerns the gene PRDX5 and ovarian carcinoma.